Published June 2020 (CAT No: VAMV015)
****This product is a summary presentation (.pdf), a forecast model (.xls)
Contents – Summary presentation (.pdf)2
[SECTION 1] Norovirus vaccines: key commercial model outputs
[SECTION 2] Norovirus: virus and disease background
[SECTION 3] Norovirus: global epidemiology – outbreak and incidence data
[SECTION 4] Norovirus: US epidemiology – outbreak and incidence data
[SECTION 5] Norovirus: EU epidemiology – outbreak and incidence data
[SECTION 6] Norovirus: ROW epidemiology – outbreak and incidence data
[SECTION 7] Norovirus: Epidemiology – focus on pediatrics/hospitalization
[SECTION 8] Norovirus: Epidemiology – focus on elderly and “at risk”/hospitalization
[SECTION 9] Norovirus: Epidemiology – focus on other groups
[SECTION 10] Norovirus vaccines: background and rationale
[SECTION 11] Norovirus vaccines: R&D pipeline
[SECTION 12] Norovirus vaccines modelling commercial potential
About VacZine Analytics
PAGES: ~200 slides fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand models x 2 (MS Excel-based)
Worksheets = >70 interconnected
|【英語タイトル】MarketVIEW: Norovirus vaccines - Global vaccine commercial opportunity assessment|
・レポート形式：Executive presentation (~200 slides.pdf) + 2 x MS-Excel forecast model(s) (.xls)
|Region Price||USD10,995 ⇒換算￥1,176,465||見積依頼/購入/質問フォーム|
Noroviruses (NoVs) called “Norwalk-like viruses” are a group of single-stranded positive sense RNA viruses and members of the family Caliciviridae. Noroviruses are transmitted from human-to-human (fecal-oral) and via food sources. They are one of the most highly infectious viruses known. In the community, NVs most commonly cause a self-limiting mild disease of short duration with gastrointestinal symptoms, usually resolving after 1 to 3 days. However, in infants, elderly and immunocompromised persons dehydration occurs requiring medical attention and/or hospital admission for the administration of IV fluids.
Globally, norovirus is associated with approximately one-fifth of all diarrhea cases, with similar prevalence in both children and adults. It is the 2nd most common cause of death in children <5 yrs and the most common cause of diarrheal death in children >5 yrs with similar patterns across WHO regions. In developing countries, norovirus is estimated to cause over 200,000 deaths annually and around 700 million illnesses. NoV outbreaks are also a well-known issue in confined environments such as long-term care facilities, hospitals, military installations and commercial cruise ship liners. In these cases, the virus can cause severe disruption and economic loss.
Because of the success of the rotavirus vaccine reducing disease burden, it is hoped a new norovirus vaccine can have a similar impact, now that the virus has taken a more prominent role. However, the SARS-CoV-2 pandemic (2020) will impact upon the norovirus vaccine timeframe and proposition. The two main programs operated by Takeda Pharmaceuticals and Vaxart were in clinical stages of testing and we await further status updates. Chinese developers are pressing ahead.
This MarketVIEW product is a comprehensive Executive presentation + MS Excel-based model(s), which forecasts the potential commercial value of Norovirus vaccines across 113 major Western and emerging markets and GAVI to 2035*. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates for all major market segments. There is a thorough review of global epidemiology, economic burden, competitive vaccine landscape. Brand new model scenarios explore segment prioritization (post-COVID-19), vaccine duration of immunity and various new adjustments. This product is ideally suited to those organisations wanting an extended, up-to-date global forecast for this vaccine opportunity.
THIS PRODUCT IS A EXECUTIVE PRESENTATION (>200 slides, .pdf) + scenario MODEL(s)